Recently, CHN-WIN Health completed an angel-plus financing round totaling tens of millions of RMB, with investment from ZGC Capital (under ZGC GROUP), Delian Capital, and Sanbo Brain Hospital. The funds raised will be used to advance the product validation and clinical translation of Neuro-IVUS, as well as the future development of ultrasound-based brain science applications.

Founded in March 2025, CHN-WIN Health is dedicated to creating a new matrix of digital AI-integrated vascular intervention devices and intelligent equipment applications. Supported by the high-quality clinical resources of Peking Union Medical College, Chinese Academy of Medical Sciences, and the cutting-edge R&D capabilities of the Institute of Biomedical Engineering, the company is dedicated to overcoming core clinical challenges in the ultrasound-based brain science and cerebrovascular intervention sector, as well as driving the rapid industrialization of high-barrier hardcore technologies.